Tango Therapeutics, Inc. · NASDAQ:TNGX
Tango Therapeutics — PDAC Investor Presentation (October 2026)
35 slides from Tango Therapeutics's conference presentation, Oct 23, 2026
Slide 1: PDAC Investor Presentation
Exhibit 99.2 PDAC Investor Presentation October 23, 2026
Slide 2: Disclaimer and safe harbor statement
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or
Slide 3: Agenda for today
Agenda for today Introduction Malte Peters, MD | President and Chief Executive Officer Vopimetostat + daraxonrasib combination data update Brian Wolpin, MD | Dana-Farber Cancer Institute & Harvard Medical School Vopimetostat registration and expansion strategy in PDAC Adam Crystal, MD, PhD | Preside
Slide 4: Introduction
Introduction Malte Peters, MD, President and Chief Executive Officer 4
Slide 5: Leadership in PRMT5 inhibition anchors broad value creation opportunity
Leadership in PRMT5 inhibition anchors broad value creation opportunity CLINICALLY PHASE 3-READY DIFFERENTIATED EXPANSION VALIDATED DESIGN Potentially Defined regulatory Demonstrated Leading the field differentiated path combinability efficacy profile 82% ORR Efficient Phase 3 design Clinical data a
Slide 6: ~60,000 U.S. pancreatic cancer patients per year
~60,000 U.S. pancreatic cancer patients per year ~60,000 1 ~36,000 ~24,000 PDAC patients MTAP-WT MTAP-deleted diagnosed/year ~30,000 2 ~20,000 1L treatment MTAP-WT MTAP-deleted Chemo-free regimens may increase patient access and ~13,800 ~9,200 2 2L treatment MTAP-WT MTAP-deleted benefit Patient popu
Slide 7: Brian Wolpin is a leader in the study and treatment of pancreatic cancer
Brian Wolpin is a leader in the study and treatment of pancreatic cancer v Professor of Medicine, Harvard Medical School v Robert T. & Judith B. Hale Chair in Pancreatic Cancer, Dana-Farber Cancer Institute v Director, Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Cen
Slide 8: Vopimetostat + daraxonrasib combination data update
Vopimetostat + daraxonrasib combination data update Brian Wolpin, MD, MPH Dana-Farber Cancer Institute & Harvard Medical School 8
Slide 9: Evolution of standard of care for pancreatic cancer
Evolution of standard of care for pancreatic cancer RAS INHIBITORS + CHEMOTHERAPY RAS INHIBITORS PRMT5 INHIBITORS Increased response rate and Current standard; RASONQUE FDA approved based prolonged durability; lower rates 1 Limited efficacy on improved PFS and OS of rash observed Current Approved +
Slide 10: Vopimetostat selectively inhibits PRMT5 in MTAP deleted cancer cells
Vopimetostat selectively inhibits the cell essential gene PRMT5 in MTAP deleted cancer cells deletion causes MTA accumulation only in cancer cells X MTAP X MTA MTA partially inhibits PRMT5 activates PRMT5 SAM MTA MTA by replacing SAM in normal cells Vopimetostat PRMT5 inhibits PRMT5 only in MTAP-del
Slide 11: PRMT5 inhibition plus RAS inhibition is synergistic preclinically
PRMT5 inhibition plus RAS inhibition is synergistic preclinically Vopimetostat + Daraxonrasib: CAPAN1 Vopimetostat + Zoldonrasib: KP4 G12V G12D MTAP-null, KRAS PDAC CDX MTAP-null, KRAS PDAC CDX 20 mpk BID vopimetostat + 20 mpk BID 5 mpk QD 20 mpk BID 100 mpk QD 100 mpk QD zoldonrasib + Vehicle Vehic
Slide 12: First PRMT5 inhibitor combined with RAS inhibitors in the clinic
First PRMT5 inhibitor combined with RAS inhibitors in the clinic Vopimetostat + daraxonrasib: Phase 1 dose escalation trial • Dose escalation range: vopimetostat Any RAS mut 200 mg – 250 mg vopimetostat QD + daraxonrasib + 100 mg daraxonrasib QD 2L+ MTAP-del/ RAS mut pancreatic • Evaluable patients
Slide 13: Patient baseline characteristics
Patient baseline characteristics Vopimetostat + daraxonrasib Vopimetostat + daraxonrasib Vopimetostat + zoldonrasib a (PDAC) N=29 (NSCLC) N=5 (PDAC) N=39 Sex, male, n (%) 12 (41.4) 3 (60) 21 (53.8) Age, years, median (range) 66 (44, 74) 55 (38, 71) 66 (37, 81) b 0 2 (6.9) - - 1 10 (34.5) 1 (20) 18 (
Slide 14: Vopimetostat + daraxonrasib in MTAP-del 2/3L PDAC: ORR 82%
Vopimetostat + daraxonrasib in MTAP-del 2/3L PDAC: ORR 82% 20 N=22 ORR 82% 0 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL1 DL1 DL1 DL2 DCR 100% -20 All responses now confirmed -40 -60 Legend: Note: 13/22 (59%) of ■ Partial Response (PR) -80 patients are 3L ■ Stable Dise
Slide 15: Consistent and promising results across PDAC and NSCLC
Consistent and promising results across PDAC and NSCLC Median duration of follow-up PDAC: 7.1 months (3.3-12.5) 20 NSCLC: 7.7 months (3.8-12.3) Line of Therapy 1 3 3 2 2 2 3 3 3 3 3 2 2 3 2 4 3 3 3 3 3 3 3 2 1 3 2 0 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL1 DL1 DL2
Slide 16: Vopimetostat + daraxonrasib in MTAP-del PDAC: 88% 9-month PFS rate
Vopimetostat + daraxonrasib in MTAP-del PDAC: 88% 9-month PFS rate 3 Key Metrics 3 3 2 • 88% 9-month PFS rate in 3 2 PDAC (95% CI: 60, 97) 2 3 • 59% of PDAC patients are 1 3L 3 2 2 3 3 3 3 2 Legend: 3 ■ Partial Response (PR) 2 ■ Stable Disease (SD) 3 3 Ongoing Therapy 1 0 1 2 3 4 5 6 7 8 9 10 11 12
Slide 17: Strong PFS trends in both second and third line MTAP-del PDAC
Strong PFS trends in both second and third line MTAPdel PDAC Key Metrics • 88% 9-month PFS rate (95% CI: 60, 97) • No disease progression in 2L patients No. at Risk LoT 0 2 4 6 8 10 12 2 7 7 5 5 3 0 3 13 13 9 5 5 3 0 a All 22 21 15 11 9 3 0 Data extract 20 August 2026. PDAC, pancreatic ductal adenoc
Slide 18: Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1
Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1 DL1: PDAC DL1:NSCLC DL2: PDAC n, (%) (n=25) (n=5) (n=4) Safety Summary Any TRAE 19 (76.0) 5 (100.0) 4 (100.0) • No new safety signals observed Grade 1-2 9 (36.0) 4 (80.0) 1 (25.0) • No discontinuations due to Grade 3 10 (40.0)
Slide 19: Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1
Vopimetostat + daraxonrasib was generally well-tolerated at dose level 1 DL1: PDAC DL1:NSCLC DL2: PDAC n, (%) (n=25) (n=5) (n=4) Safety Summary TRAEs occurring in All Grade All Grade All Grade ≥15% of Patients Grades 3 Grades 3 Grades 3 • No new safety signals observed a Rash 11 (44.0) - 5 (100.0) -
Slide 20: Vopimetostat + daraxonrasib demonstrated favorable RAS associated safety profile
Vopimetostat + daraxonrasib demonstrated favorable RAS associated safety profile Vopimetostat 200 mg + daraxonrasib 100 mg (PDAC) Pharmacokinetics and safety n=25 (TRAEs, % patients, Grade 1-3) Dose level 1 • Daraxonrasib AUC: 4303 Stomatitis/mucositis 48% hr*ng/ml (n=20, CV 40%) Rash 44% − Similar
Slide 21: Clinically meaningful exposures and limited variability supportive of Phase 3
Daraxonrasib (ng/ml) Clinically meaningful exposures and limited variability supportive of Phase 3 development Time (Hour) CV AUC0-24h (ng*h/mL) | Mean ± SD Vopimetostat DL1 (n=18) 38% 3815 ± 1444 Daraxonrasib DL1 (n=20) 40% 4303 ± 1721 Data extract 20 August 2026. 21 Vopimetostat (ng/ml)
Slide 22: Vopimetostat registration path
Vopimetostat registration path Adam Crystal, MD, PhD, President of Research and Development 22
Slide 23: Vopimetostat + daraxonrasib: anticipated path to PDAC registration
Vopimetostat + daraxonrasib: anticipated path to PDAC registration LEAD PROGRAM Vopimetostat + daraxonrasib 1 ~20,000 Defined 1L registration path MTAP-del patients annually U.S. Design informed by FDA guidance Larger near-term PDAC opportunity Favorable safety + 82% 88% ORR* 9-mo PFS rate full targ
Slide 24: Phase 3 study in 1L, MTAP-del PDAC anticipated to start 1H 2027
Phase 3 study in 1L, MTAP-del PDAC anticipated to start 1H 2027 Primary Endpoints Vopimetostat + daraxonrasib 1L MTAP-del • Dual primary endpoints: metastatic 1:1 ORR and PFS randomization pancreatic cancer N = 484 • OS as key secondary SOC chemo endpoint • Dose level 1 selected Key inclusion criter
Slide 25: Advancing development path in 1L and 2L PDAC
Advancing development path in 1L and 2L PDAC Vopimetostat + daraxonrasib PDAC front line strategy supported by regulatory discussions Study Objectives & Path Details Primary Readout Potential Regulatory Outcomes Randomized ORR • Potential 1L approval Controlled Trial vs. PFS SOC chemo • Assess contr
Slide 26: Leadership in PRMT5 inhibition
Leadership in PRMT5 inhibition Adam Crystal, MD, PhD 26
Slide 27: Leadership in PRMT5 supports opportunities for indication expansion
Leadership in PRMT5 supports opportunities for indication expansion Biologic PDAC Additional Vopimetostat + RAS inhibitors Foundation Opportunities • Clinical activity shows that • PRMT5i + RAS/MAPK • Clinical synergy with MAPK a the combination biology inhibition is synergistic pathway may extend c
Slide 28: Vopimetostat inhibited PRMT5 in MTAP WT cells, clinically
Vopimetostat inhibited PRMT5 in MTAP WT cells, clinically Pharmacokinetics Pharmacodynamics Safety At 200 mg vopimetostat Vopimetostat inhibited MTAP WT tissue results in on target MTAP del tumor PRMT5 in MTAP wild type related adverse events: cells • Fatigue • Clinical exposure in • Thrombocytopeni
Slide 29: Vopimetostat potentiates daraxonrasib in MTAP-WT PDAC cell lines
Vopimetostat potentiates daraxonrasib in MTAP-WT PDAC cell lines at the exposure achieved clinically Vopimetostat + daraxonrasib in vitro activity Key observations • Improved clinical activity in MTAP-WT PDAC cell lines with vopimetostat + daraxonrasib at clinical 35% exposure greater reduction from
Slide 30: Efficient path to expand the PRMT5 opportunity
Efficient path to expand the PRMT5 opportunity Potential for combination benefit to extend beyond MTAP-deleted cancers Clinically Enroll MTAP-WT Potential to reach validated PDAC cohort more patients in combination PDAC & beyond Anticipated ~25-patient POC cohort vopimetostat + MTAP-WT proof of conc
Slide 31: Upcoming milestones and financial highlights
Upcoming milestones and financial highlights Matthew Gall, Chief Financial Officer 31
Slide 32: Near-term anticipated milestones support advancement of vopimetostat
Near-term anticipated milestones support advancement of vopimetostat clinical development and efficient expansion opportunities Advance NSCLC Expand RAS Opportunity Advance Lead PDAC Program development strategy 2H26 1H27 January 2027 Initiate Phase 1/2 Initiate Phase 3 vopimetostat + Release TNG456
Slide 33: Conclusion
Conclusion Malte Peters, MD, President and Chief Executive Officer 33
Slide 34: Compelling PDAC data support our registration strategy and broader franchise potential
Compelling PDAC data support our registration strategy and broader franchise potential VALIDATED REGISTRATION- LAUNCH BROADER CLINICAL PROFILE DIRECTED PREPARATION VOPIMETOSTAT DEVELOPMENT FRANCHISE POTENTIAL Compelling activity, Focus shifts from Organizational Combinability and MTAP-WT durability
Slide 35: Tango Therapeutics
Bij TANGO therapeutics
Tango Therapeutics — PDAC Investor Presentation (October 2026) on 6ix